Ivabradine is indicated to control heart rate in otherwise optimally treated patients with chronic heart failure (CHF) and reduced ejection fraction. However, data on its effectiveness outside clinical trials and longer-term effects are scarce.
We performed a prospective cohort study involving 249 German resident cardiologists and analyzed the 1-year effectiveness and safety of ivabradine used in CHF outpatients. Data on symptoms, quality of life, and hospitalizations were collected.
In total, 767 CHF patients were enrolled to receive ivabradine twice daily, of whom 684 (90%) were still on ivabradine at study end (mean treatment duration 11.2 months). The cohort was representative of CHF patients seen in clinical practice in terms of age, risk factor profile, and comorbidities. Concomitant beta-blocker therapy was prescribed in 497 patients (65%). After one year, compared to baseline, heart rate in ivabradine-treated patients was 16 bpm lower. This reduction was associated with a significant improvement in NYHA class, and less frequent signs of decompensation (36% to 8%). The proportion of hospitalized patients within 1 year decreased from 23% before treatment, to 5% with ivabradine therapy. These improvements in clinical status were accompanied by a reduction in BNP and an increase in LVEF (+5.1% at 1 year). Quality of life was significantly improved in all measured dimensions. Adverse drug reactions were noted in 26 patients (3%), and were in line with the known safety profile of ivabradine.
Ivabradine was effective and well-tolerated in CHF patients seen in clinical practice throughout 1 year of treatment.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to International Journal of Cardiology
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC.Eur. Heart J. 2016; 37: 2129-2200
- Heart failure: the commonest reason for hospital admission in Germany: medical and economic perspectives.Dtsch. Arztebl. Int. 2009; 106: 269-275
- Heart failure epidemiology 2000–2013: insights from the German Federal Health Monitoring System.Eur. J. Heart Fail. 2016; 18: 1009-1018
- Demographic change and its impact on the health-care budget for heart failure inpatients in Germany during 1995–2025.Herz. 2013; 38: 862-867
- Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial.Lancet. 2010; 376: 886-894
- I(f) inhibition in cardiovascular diseases.Adv. Pharmacol. 2010; 59: 53-92
- Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled trial.Lancet. 2010; 376: 875-885
- Impact of “off-label” use of ivabradine on exercise capacity, gas exchange, functional class, quality of life, and neurohormonal modulation in patients with ischemic chronic heart failure.J. Cardiovasc. Pharmacol. Ther. 2010; 15: 349-355
- Heart rate reduction with ivabradine and health related quality of life in patients with chronic heart failure: results from the SHIFT study.Eur. Heart J. 2011; 32: 2395-2404
- Ivabradine treatment in a chronic heart failure patient cohort: symptom reduction and improvement in quality of life in clinical practice.Adv. Ther. 2014; 31: 961-974
- BNP consensus panel 2004: a clinical approach for the diagnostic, prognostic, screening, treatment monitoring, and therapeutic roles of natriuretic peptides in cardiovascular disease.Congest. Heart Fail. 2004; 10: 1-30
- Effect of ivabradine on recurrent hospitalization for worsening heart failure in patients with chronic systolic heart failure: the SHIFT study.Eur. Heart J. 2012; 33: 2813-2820
- The effect of digoxin on mortality and morbidity in patients with heart failure.N. Engl. J. Med. 1997; 336: 525-533
- Digoxin and clinical outcomes in systolic heart failure patients on contemporary background heart failure therapy.Am. J. Cardiol. 2008; 102: 1356-1360
- Effectiveness and safety of digoxin among contemporary adults with incident systolic heart failure.Circ. Cardiovasc. Qual. Outcomes. 2013; 6: 525-533
- Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy.Eur. Heart J. 2011; 32: 2507-2515
- Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12,440 patients of the ESC Heart Failure Long-Term Registry.Eur. J. Heart Fail. 2013; 15: 1173-1184
- Physicians' adherence to guideline- recommended medications in heart failure with reduced ejection fraction: data from the QUALIFY global survey.Eur. J. Heart Fail. 2016; 18: 514-522
- Is heart rate adequately controlled in chronic systolic heart failure patients in Germany? Results from a nationwide survey (INDICATE).Dtsch. Med. Wochenschr. 2015; 140: e48-e55
- Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose?.J. Am. Coll. Cardiol. 2012; 59: 1938-1945
- Impact of heart failure and left ventricular systolic dysfunction on quality of life: a cross-sectional study comparing common chronic cardiac and medical disorders and a representative adult population.Eur. Heart J. 2002; 23: 1867-1876
- Health status identifies heart failure outpatients at risk for hospitalization or death.J. Am. Coll. Cardiol. 2006; 47: 752-756
- The enigma of quality of life in patients with heart failure.Int. J. Cardiol. 2008; 125: 407-409
- The effect of beta-blocker therapy on quality of life in heart failure patients: a systematic review and meta-analysis.Pharmacoepidemiol. Drug Saf. 2007; 16: 152-159
- Effect of carvedilol, ivabradine or their combination on exercise capacity in patients with heart failure (the CARVIVA HF trial).Int. J. Cardiol. 2011; 151: 218-224
- Impact of Ivabradine on health-related quality of life of patients with ischaemic chronic heart failure.Curr. Vasc. Pharmacol. 2016; 14: 481-486
- Determinants of under-reporting of adverse drug reactions: a systematic review.Drug Saf. 2009; 32: 19-31
- EURObservational Research Programme: regional differences and 1-year follow-up results of the Heart Failure Pilot Survey (ESC-HF Pilot).Eur. J. Heart Fail. 2013; 15: 808-817
Published online: April 11, 2017
Accepted: March 28, 2017
Received: January 5, 2017
© 2017 Published by Elsevier Ireland Ltd.